Current Role of Chemotherapy in Nonmetastatic Nasopharyngeal Cancer

Bhattacharyya, Tapesh; Babu, Geethu; Kainickal, C.T.

doi:10.1155/2018/3725837

Cited by 25 publications

(17 citation statements)

References 38 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HNC is a common malignant disease with relatively high morbidity and mortality[1, 5]. Although the advances in radiotherapy technology have greatly improved the therapeutic effects on patients with HNC, local recurrence still remains the main reason for treatment failure in this group of patients and more than 25% of them finally develop distant metastases[14, 15, 48]. Therefore, early diagnosis and precise prognosis of patients with HNC are very important and urgently needed.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis

et al. 2019

View full text Add to dashboard Cite

Cytokeratin fraction 21–1 (CYFRA 21–1) has been widely studied as an important biomarker in non-small cell lung cancer for both diagnosis and prognosis. Many studies have also assessed the clinical applications of CYFRA 21–1 in head and neck cancer, but the diagnostic and prognostic values of CYFRA 21–1 are not yet fully established. This pooled analysis aims at evaluating the diagnostic accuracy and prognostic applications of CYFRA 21–1 in patients with head and neck cancer. A systematic retrieval of literatures was conducted without time or language restrictions by searching PubMed, EMBASE, Web of Science, Cochrane library and China National Knowledge Infrastructure. Twenty studies were eligible for systematic review, of which 14 conformed for diagnostic analysis and 7 for prognostic analysis. The pooled sensitivity and specificity of CYFRA 21–1 analysis were 0.53 (95% CI: 0.39–0.67) and 0.97 (95% CI: 0.93–0.99), respectively. A high level of CYFRA 21–1 was significantly correlated with shorter overall survival (HR 1.33, 95% CI: 1.13–1.56) and disease-free survival (HR 1.48; 95%CI: 1.10–1.97). Current evidence indicates that the level of CYFRA 21–1 in the serum could be used as an indicator for monitoring tumor status and evaluating its curative effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The difference in OS rate between patients with detectable and undetectable plasma EBV DNA levels appears to be more stark using post-treatment plasma EBV DNA (21.0%-76.1%) [85][86][87][88]93,95] than using pre-treatment EBV DNA (6.6%-32.8%) [85][86][87][88][89] (Tables 4 and 5). It was hypothe-sized that patients with persistently elevated plasma EBV DNA levels after definitive intensity-modulated radiotherapy may have minimal residual disease [95] and hence, may benefit from adjuvant chemotherapy [97]. However, a randomized phase III study led by Chan et al [93] did not show any prolonged recurrence free survival with adjuvant chemotherapy (cisplatin and gemcitabine) following definitive treatment among patients with detectable post-treatment plasma EBV DNA.…”

Section: Post-treatment Plasma Ebv Dna and Other Ebv Status Detectionmentioning

confidence: 99%

Clinical utility of Epstein‐Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma

Tan

Phua

Soong

et al. 2020

Cancer Communications

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor ubiquitously associated with the Epstein-Barr virus (EBV), which is highly prevalent in South China, Southeast Asia, and North Africa. Despite being a highly radio-sensitive and treatable cancer, a majority of NPC patients are diagnosed in their advanced stage, and locoregional and distant relapses following definitive treatment contribute largely to cancer-specific mortality among these patients. Given that EBV-driven NPC is the predominant variant seen in endemic regions, various EBV detection methods have been developed and are utilized in screening, prognostication, and post-treatment surveillance of NPC patients. While the Immunoglobulin A (IgA) serology assay is the most extensively studied EBV

show abstract

“…The combination of chemotherapy with radiotherapy has been widely accepted as a treatment modality for advanced NPC, but it is still not optimal. The 5year life expectancy in stages I, II, III, and IV tumors is 95-70%, 83-65%, 76-54%, and 56-29% [2,15].…”

Section: Picture 3 Nasopharyngeal Histopathologymentioning

confidence: 99%

Visual Impairment in Nasopharyngeal Carcinoma

Akbar

Utama

2020

IJNPC

View full text Add to dashboard Cite

Introduction: he most common complaint in almost half of nasopharyngeal carcinoma (NPC) patients is a lump in the neck. Neurological symptoms occur less frequently, whereas blindness occurs in only less than one percent of cases. Case report: A 47-year-old male had complained about headache, nasal voice, and blindness in the right eye since a month ago. An examination found a mass in the right nasal cavity, right neck lymph nodes enlargement, damage to the right oculomotor (III), trochlear (IV), and abducens (VI) nerve, and right optic nerve (II). On funduscopy, the right macular reflex decreased. On CT scan there was a right nasopharyngeal mass extending to intracranial and right intraorbital spaces. Conclusion: There was a direct infiltration of NPC into surrounding and intracranial structures. Unilateral blindness might be caused by expansion to middle cerebral fossa and orbita. It could also be caused by optic nerve compression from surrounding tumor tissue.

show abstract

Current Role of Chemotherapy in Nonmetastatic Nasopharyngeal Cancer

Cited by 25 publications

References 38 publications

Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis

Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis

Clinical utility of Epstein‐Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma

Visual Impairment in Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About